The participants with AD and CVD were randomized to treatment with rilapladib, another potent Lp‐PLA2 inhibitor developed by GSK, or placebo once daily for 24 weeks on top of their stable background therapy. This evidence concerns the gene PLA2G7 and Alzheimer disease.